EPRX
HealthcareEupraxia Pharmaceuticals Inc.
$7.68
+$0.11 (+1.45%)
Jan 5, 2026
Price History (1Y)
Analysis
Eupraxia Pharmaceuticals Inc. (EPRX) is a biotechnology company within the healthcare sector. With a market capitalization of $393.50M and 33 employees, it operates on a relatively small scale compared to its peers. The company's financial health is concerning, with profitability metrics indicating significant losses. The operating margin and profit margin are both at 0.0%, suggesting substantial expenses offsetting revenue. Furthermore, the net income (TTM) stands at $-31,709,946, while EBITDA is $-29,603,326. On the balance sheet side, Eupraxia Pharmaceuticals has a debt-to-equity ratio of 0.19 and cash of $88.96M. The company's valuation metrics raise questions about its future performance. The forward P/E ratio is -12.39, which may indicate that investors are anticipating significant losses or difficulties for the company. Additionally, the EV/EBITDA ratio stands at -10.97, suggesting a high debt burden relative to earnings.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Visit website →Key Statistics
- Market Cap
- $393.50M
- P/E Ratio
- N/A
- 52-Week High
- $8.00
- 52-Week Low
- $2.68
- Avg Volume
- 121.17K
- Beta
- 1.50
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- Canada
- Employees
- 33